DreamCIS, Inc (223250) Fair Value & Analysis
Healthcare · KR · Market cap 69.3B KRW
Fair value as of: Jul 22, 2026
From 24 valuation models · updated 19 days ago
Fair value updated Jul 22, 2026, revised from 5,090 KRW to 4,925 KRW (−3.3%) since Jul 7, 2026. Share price +7.4% over the past month.
A solid business, screening 42% undervalued on our models.
What matters now
- The price is below even our cautious bear case (3,694 KRW). The market is more pessimistic than our downside scenario.
- Solid quality (58/100) at a price below fair value, the discount is the argument here, not the business quality.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 22, 2026.
How to read this chart
60‑month range 2,378 KRW – 7,840 KRW · fair‑value band 3,694 KRW – 6,156 KRW · the 3,475 KRW price screens below the 4,925 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 22, 2026.
Analysis
DreamCIS, Inc (223250) currently trades at 3,475 KRW, while our model-based Fair Value estimate is 4,925 KRW, implying the stock looks roughly 41.7% undervalued today. The Quality Score stands at 58/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, DreamCIS, Inc generated revenue of 23.0B KRW at a net margin of 19.1%. Revenue grew 22.9% year over year. It earns a return on equity of 23.2%. Fundamentals as of Jul 22, 2026
Our scenario range runs from 3,694 KRW (bear case) to 6,156 KRW (bull case); at 3,475 KRW, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 60% below its 52-week high and 12% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 11% fair-value upside, at 42%, 223250 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: DCF Models (11,551 KRW) versus Asset-Based (2,081 KRW). Highest evidence: Growth DCF (80).
Notify me when 223250 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 22, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 59 · Market factors (momentum, volatility) 27
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
DreamCIS, Inc. operates as a clinical research organization in South Korea. It offers clinical development services; biostatics, data and project management, pharmacovigilance, medical writing, site start up, clinical monitoring, Dreamtrial, IWRS, and quality assurance services; medical device development services; and regulatory consulting services.
Full company description
DreamCIS, Inc. operates as a clinical research organization in South Korea. It offers clinical development services; biostatics, data and project management, pharmacovigilance, medical writing, site start up, clinical monitoring, Dreamtrial, IWRS, and quality assurance services; medical device development services; and regulatory consulting services. The company was founded in 2000 and is headquartered in Seoul, South Korea. DreamCIS, Inc. operates as a subsidiary of Hangzhou Tigermed Consulting Co., Ltd.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
DreamCIS, Inc reported revenue of 66.6B KRW in FY2025 versus 26.2B KRW in FY2021, a compound +26.3%/yr. Reported net income was 7.1B KRW in FY2025, compounding +21.9%/yr from FY2021.
Watch 223250: get an alert when its fair value changes →
Peer Group
Medical Care Facilities · 261 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Care Facilities median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $378.85 | $554.93 | +46% |
| Fresenius SE FRE | €41.73 | €32.15 | -23% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 235.00 SAR | 112.37 SAR | -52% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.58 SGD | 1.44 SGD | -44% |
| Tenet Healthcare Corporation THC | $194.91 | $338.05 | +73% |
| Rede D'Or São Luiz S.A RDOR3 | R$36.01 | R$47.31 | +31% |
| DaVita Inc DVA | $231.61 | $255.97 | +11% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,955 | ₹2,955 | -67% |
| Fresenius Medical Care AG FMS | $24.68 | $45.60 | +85% |
| Aier Eye Hospital Group 300015 | ¥8.68 | ¥7.67 | -12% |
Compare DreamCIS, Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is DreamCIS, Inc (223250) overvalued or undervalued?
What is the fair value of 223250?
What is the quality score of 223250?
What is the revenue of DreamCIS, Inc (223250)?
What is the net profit margin of 223250?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track DreamCIS, Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.